Enhanced Oncolytic Virus with Improved Safety and Anticancer Effect
Legal Citation
Summary of the Inventive Concept
An oncolytic virus with enhanced safety and anticancer effect through targeted gene modifications, providing improved treatment options for cancer patients.
Background and Problem Solved
The original patent disclosed an oncolytic virus with improved safety and anticancer effect, but it had limitations in terms of efficacy and targeting. The new inventive concept addresses these limitations by introducing additional gene modifications that enhance the virus's anticancer effect, safety, and targeting ability.
Detailed Description of the Inventive Concept
The new oncolytic virus comprises a nucleotide sequence encoding a truncated fragment of HSV1-TK, with additional gene modifications that enhance the virus's anticancer effect, safety, and targeting ability. The virus can be administered in combination with chemotherapy agents, and the chemotherapy agent can be selected from the group consisting of doxorubicin, cisplatin, and carboplatin. The truncated fragment of HSV1-TK can be any one of fragments in which 20 to 200 amino acid residues are consecutively deleted from the C-terminal of the amino acid sequence of SEQ ID NO: 1, and further comprising a nucleotide sequence encoding a gene that enhances the anticancer effect of the virus. Alternatively, the truncated fragment of HSV1-TK can be any one of fragments in which 10 to 50 amino acid residues are consecutively deleted from the N-terminal of the amino acid sequence of SEQ ID NO: 1, and further comprising a nucleotide sequence encoding a gene that enhances the safety of the virus.
Novelty and Inventive Step
The new inventive concept is novel and non-obvious over the original patent because it introduces additional gene modifications that enhance the virus's anticancer effect, safety, and targeting ability, providing a significant improvement over the existing technology.
Alternative Embodiments and Variations
The inventive concept can be implemented in various ways, such as using different types of viruses, modifying different genes, or using different chemotherapy agents. Additionally, the virus can be engineered to target specific types of cancer cells or to have a specific tropism.
Potential Commercial Applications and Market
The enhanced oncolytic virus has significant commercial potential in the cancer treatment market, particularly in the areas of targeted therapy and immunotherapy. The market for cancer treatment is growing rapidly, and the new inventive concept is well-positioned to capture a significant share of this market.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K35/768 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K31/708 |
| C | C12 | C12N15/86 |
| C | C12 | C12N2710/24111 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Virology, oncology, and genetic engineering, with a focus on oncolytic virus design and modification for cancer treatment. Requires advanced knowledge of molecular biology, gene recombination techniques, and viral vector engineering
Person of Ordinary Skill (PHOSITA) Profile
A researcher with a PhD in molecular biology or virology, experienced in genetic engineering, viral vector design, and cancer therapeutics. Familiar with gene modification techniques, viral tropism, and targeted cancer therapies
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core technology. The modifications to the HSV1-TK truncation, combined with additional gene enhancements, follow standard approaches in oncolytic virus engineering. The proposed changes represent incremental improvements using known genetic manipulation techniques that would be obvious to a skilled researcher in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,585 |
|---|---|
| Title | Oncolytic virus improved in safety and anticancer effect |
| Assignee(s) | BIONOXX INC. |